Lecap Asset Management Ltd. Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Lecap Asset Management Ltd. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,020 shares of the biopharmaceutical company's stock after selling 3,030 shares during the period. Lecap Asset Management Ltd.'s holdings in Gilead Sciences were worth $926,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new position in Gilead Sciences during the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the fourth quarter worth $28,000. Finally, Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently commented on GILD. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Robert W. Baird upped their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. UBS Group upped their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Finally, Citigroup initiated coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective on the stock. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $98.39.

Gilead Sciences Stock Down 2.0 %

NASDAQ:GILD traded down $2.00 during trading hours on Friday, hitting $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The stock has a fifty day moving average of $93.04 and a 200-day moving average of $86.76. The stock has a market capitalization of $119.69 billion, a P/E ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm's revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.